Sage Journals: Discover world-class research

Abstract

A prior epidemiological study identified a reduction in opioid overdose deaths in US states that legalized medical cannabis (MC). One theory to explain this phenomenon is a potential substitution effect of MC for opioids. This study evaluated whether this substitution effect of MC for opioids also applies to other psychoactive medications. New England dispensary members (n = 1,513) completed an online survey about their medical history and MC experiences. Among respondents that regularly used opioids, over three-quarters (76.7%) indicated that they reduced their use since they started MC. This was significantly (p < 0.0001) greater than the patients that reduced their use of antidepressants (37.6%) or alcohol (42.0%). Approximately two-thirds of patients decreased their use of anti-anxiety (71.8%), migraine (66.7%), and sleep (65.2%) medications following MC which significantly (p < 0.0001) exceeded the reduction in antidepressants or alcohol use. The patient’s spouse, family, and other friends were more likely to know about their MC use than was their primary care provider. In conclusion, a majority of patients reported using less opioids as well as fewer medications to treat anxiety, migraines, and sleep after initiating MC. A smaller portion used less antidepressants or alcohol. Additional research is needed to corroborate these self-reported, retrospective, cross-sectional findings using other data sources.

Keywords

Marijuana opioids stigma

Get full access to this article

View all access options for this article.

References

Aggarwal

(2013) Cannabinergic pain medicine: A concise clinical primer and survey of randomized controlled trial research. Clin J Pain 29: 162–171.

American Psychiatric Association (2013) DSM-5: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association.

Bachhuber

Saloner

Cunningham

. (2014) Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med 174: 1668–1673.

Boehnke

Litinas

Clauw

(2016) Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain 17: 739–744.

Bottorff

Bisell

LJL

Balneaves

. (2013) Perceptions of cannabis as a stigmatized medicine: A qualitative descriptive study. Harm Reduct J 10: 2.

Bradford

(2016) Medical marijuana laws reduce prescription medication use in Medicare Part D. Health Aff 35: 1230–1236.

Center for Behavioral Health Statistics and Quality (2015) Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15–4927, NSDUH Series H-50). Available at: http://www.samhsa.gov/data/ (accessed 13 March 2017).

Cichewicz

(2004) Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 74: 1317–1324.

Dowell

Haegerich

Chou

(2016) CDC guideline for prescribing opioids for United States, 2016. MMWR Recomm Rep 65: 1–49.

10.

Elikottil

Gupta

(2009) The analgesic potential of cannabinoids. J Opioid Manag 5: 341–357.

11.

ElSohly

Slade

(2005) Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci 78: 539–548.

12.

Epstein

Preston

(2015) No evidence for reduction of opioid-withdrawal symptoms by cannabis smoking during a methadone dose taper. Am J Addict 24: 323–328.

13.

Eysenbach

(2004) Improving the quality of web surveys: The checklist for reporting results of internet e-surveys (CHERRIES). J Med Internet Res 6: e34.

14.

Fairman

(2016) Trends in registered medical marijuana participation across 13 US states and District of Columbia. Drug Alcohol Depend 159: 72–79.

15.

Fattore

Cossu

Spano

. (2004) Cannabinoids and reward: Interactions with the opioid system. Crit Rev Neurobiol 16: 147–158.

16.

Fride

Foox

Rosenberg

. (2003) Milk intake and survival in a newborn cannabinoid CB1 receptor knockout mice: Evidence for a “CB3” receptor. Eur J Pharmacol 461: 27–34.

17.

Frieden

Houry

(2016) Reducing the risks of relief - The CDC opioid-prescribing guideline. N Eng J Med 374: 1501–1504.

18.

Guzman

(2003) Cannabinoids: Potential anticancer agents. Nat Rev Cancer 3: 745–755.

19.

Hamill

Lin

Hagmann

. (2009) PET imaging studies in rhesus monkey with the cannabinoid-1 (CB₁) receptor ligand [¹¹C]CB-119. Mol Imaging Biol 11: 246–252.

20.

Haroutounian

Ratz

Ginosar

. (2015) The effect of medicinal cannabis on pain and quality of life outcomes in chronic pain: A prospective open-label study. Clin J Pain 32: 1036–1043.

21.

Hillig

Mahlberg

(2004) A chemotaxonomic analysis of cannabinoid variation in cannabis (Cannabacae). Am J Bot 91: 966–975.

22.

Karst

Wippermann

Ahrens

(2010) Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs 70: 2409–2438.

23.

Lucas

Walsh

Crosby

. (2016) Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors. Drug Alcohol Rev 35: 326–333.

24.

Lutge

Gray

Siegfried

(2013) The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database Syst Rev 4: CD005175.

25.

Mackie

(2008) Cannabinoid receptors: Where they are and what they do. Neuroendocrinology 20: 10–14.

26.

Mikuriya

(2004) Cannabis as a substitute for alcohol: A harm-reduction approach. J Cannabinoid Therapeutics 4: 79–93.

27.

Moncrieff

Kirsh

(2015) Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences. Contemp Clin Trials 43: 60–62.

28.

Morales

Jagerovic

(2016) Advances towards the discovery of GPR55 ligands. Cur Med Chem 23: 2087–2100.

29.

Nunberg

Kilmer

Pacula

. (2011) An analysis of applicants presenting to a medical marijuana specialty practice in California. J Drug Policy Anal 4: 1–16.

30.

Ogden

Carroll

Kit

. (2014) Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA 311: 806–814.

31.

Pertwee

(2009) Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Brit J Pharmacol 156: 397–411.

32.

Piper

Desrosiers

Lipovsky

. (2016) Use and misuse of opioids in Maine: Results from pharmacists, the Prescription Monitoring, and the Diversion Alert programs. J Stud Alcohol Drugs 77: 556–565.

33.

Reiman

(2007) Medical cannabis patients: Patient profiles and health care utilization patterns. Complement Health Pract Rev 12: 31–50.

34.

Reiman

(2009) Cannabis as a substitute for alcohol and other drugs. Harm Reduct J 6: 35.

35.

Rhyne

Anderson

Gedde

. (2016) Effects of medical marijuana on migraine headache frequency in an adult population. Pharmacotherapy 36: 505–510.

36.

Rösner

Hackl-Herrwerth

Leucht

. (2010a) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 12: CD001867.

37.

Rösner

Hackl-Herrwerth

Leucht

. (2010b) Acamprosate for alcohol dependence. Cochrane Database Syst Rev 9: CD004332.

38.

Simpatico

(2015) Vermont responds to its opioid crisis. Prevent Med 80: 10–11.

39.

Sorg

Greenwald

Wren

(2016) Patterns of drug-induced mortality in Maine, 2015 update. Maine Policy Review 25: 34–46.

40.

Stahl

(2013) Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications. 4th ed. Cambridge: Cambridge University Press.

41.

Stout

Cimino

(2014) Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: A systematic review. Drug Metab Rev 46: 86–95.

42.

Subbaraman

(2014) Can cannabis be considered a substitute medication for alcohol? Alcohol and Alcoholism 49: 292–298.

43.

Todaro

(2012) Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Comp Canc Netw 10: 487–492.

44.

Zaller

Topletz

Frater

. (2015) Profiles of medical cannabis patients attending compassion centers in Rhode Island. J Psychoactive Drugs 47: 18–23.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.15 MB

Substitution of medical cannabis for pharmaceutical agents for pain,anxiety,and sleep

Abstract

Keywords

Get full access to this article

References

Supplementary Material